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Background. IgA nephropathy (IgAN), characterized by
mesangial IgA deposition, runs a variable clinical course with
tubulointerstitial damage and renal failure in no less than
30% of patients. Histologically, IgA is rarely detected in re-
nal tubules. The direct toxicity by IgA on renal tubules remains
uncertain. We hypothesize that mediators released from human
mesangial cells (HMC) triggered by IgA deposition may lead
to activation of proximal tubular epithelial cells (PTEC).
Methods. The binding of IgA to PTEC or HMC was assessed
by flow cytometry. IgA-HMC medium was prepared by col-
lecting the spent medium in which growth arrested HMC were
incubated with IgA isolated from patients with IgAN, healthy
control subjects, or other nephritic control patients. PTEC was
cultured with the IgA-HMC medium in the presence or ab-
sence of neutralizing antibodies to TNF-a, IL-1b , TGF-b , or
PDGF. Gene expression and protein synthesis of TNF-a, MIF,
or ICAM-1 by PTEC were determined by RT-PCR and ELISA,
respectively.
Results. The binding of IgA isolated from patients with IgAN
to PTEC was increased when compared to binding of IgA from
healthy control subjects (P < 0.005). However, the binding to
PTEC was less than one tenth that of HMC in IgAN. The bind-
ing to PTEC was not mediated through known IgA receptors,
as shown by competitive binding assays and gene expression
of the receptors. Despite the in vitro binding, PTEC cultured
with isolated IgA exhibited no increased cell proliferation or en-
hanced synthesis of TNF-a, MIF, or sICAM-1. However, when
PTEC were cultured with IgA-HMC medium prepared from
IgAN patients, there was enhanced proliferation of PTEC (P <
0.001) and increased synthesis of TNF-a, MIF, and sICAM-1
when compared with PTEC cultured with IgA-HMC medium
from control subjects (P < 0.001). The synthesis of MIF and
sICAM-1 by PTEC cultured with IgA-HMC medium was re-
duced by neutralizing antibodies to TNF-a (P < 0.001) but not
by neutralizing antibodies to IL-1b , TGF-b , or PDGF.
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Conclusion. Our finding implicates that TNF-a released from
the mesangium after IgA deposition activates renal tubular
cells. The glomerulotubular communication could play an im-
portant role in the pathogenesis of tubulointerstitial damage in
IgAN.
IgA nephropathy (IgAN), the most common form of
glomerulonephritis, is one of the leading causes of renal
failure in many parts of the world. The disease is char-
acterized by mesangial deposition of pathogenic poly-
meric IgA1 (pIgA1) [1], proliferation of mesangial cells,
increased synthesis of extracellular matrix (ECM), and
infiltration of macrophage, monocytes, and T cells [2, 3].
IgAN runs a highly variable clinical course with a slowly
relentless and progressive renal failure in 30% to 50% of
patients within 30 years after first clinical presentation [4].
A subgroup of IgAN with severe tubulointerstitial atro-
phy is often associated with the most rapid progression to
end-stage renal failure [5]. The severity of tubulointersti-
tial damage in different glomerulonephritides, including
IgAN, correlates closely with the declining renal function
and the long-term clinical outcome [6–9]. Inflammation
elicited by infiltrating mononuclear cells plays an impor-
tant role in the development of glomerular and tubuloin-
terstitial injury in IgAN [10–13]. Proteinuria is a potent
inflammatory stimulus of proximal tubular epithelial cells
(PTEC). Our recent work has provided experimental ev-
idence to suggest a tubuloglomerular “cross-talk” mech-
anism, involving different soluble factors, and is likely to
operate in different glomerular and interstitial nephritis
[14]. However, high-grade or nephrotic-range proteinuria
is not a common clinical feature of IgAN. Furthermore,
IgA deposits are rarely detected in the tubulointersti-
tium [15, 16]. Hence, the most important and central
question is how IgA deposits in glomerular mesangial
cells lead to subsequent tubulointerstitial damage result-
ing in end-stage renal failure. Normally, the glomerular
barrier is impermeable to proteins. However, increase
in glomerular barrier pore size that allowed the passage
of proteins to the tubular lumen is observed in various
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glomerular diseases [17]. Hence, the tubulointerstitial
damage in IgAN may be the result of cross-talk or com-
munication between the glomerular and the tubular com-
partment due to increased passage of mediators through
the glomerular barrier. Mediators released by infiltrat-
ing cells or resident kidney cells (including mesangial
cells and PTEC) are directly responsible for activation
of PTEC. The inflammatory cascade may be amplified
by local production of chemokines, cytokines, adhesion
molecules, and extracellular matrix components, which
ultimately leads to progressive loss of kidney function
[18–20]. So far, the interaction or cross-talk between these
individual components that may lead to tubulointerstitial
injury in IgAN has not been addressed. In this study, we
first explored the expression of IgA receptors and exam-
ined any direct effect of IgA molecules on PTEC. The
pathophysiologic effects on PTEC by mediators released
from mesangial cells triggered by IgA deposition were
also studied.
METHODS
Materials
Jacalin agarose was purchased from Pierce (Rockford,
IL, USA). Rosewell Park Memorial Institute Medium
(RPMI 1640 medium), Dulbecco’s modified Eagle’s
medium and Ham’s F12 medium (DMEM/F12 medium)
and fetal bovine serum (FBS) were obtained from Life
Technologies (Rockville, MD, USA). F(ab’)2 fragment
of FITC-conjugated rabbit antihuman IgA and FITC-
conjugated preimmune rabbit Ig antibodies were ob-
tained from Dako (Kyoto, Japan). 4’,6’-diamidino-2-
phenylindole hydrochloride (DAPI) was obtained from
Molecular Probe (Eugene, OR, USA). Anti-secretory
component (Anti-sc) was obtained from ICN Phar-
maceuticals (Aurora, OH, USA). Anti-CD89 blocking
antibody (Clone My43) was obtained from Medarex
(Annandale, NJ, USA). Total IgA was prepared by affin-
ity chromatography with jacalin agarose. Polymeric IgA
(pIgA) and monomeric IgA (mIgA) were further sepa-
rated by size exclusion chromatography using fast pro-
tein liquid chromatography as previously described [21].
The endotoxin content in the IgA preparations and the
spent medium were determined using Limulus amebo-
cyte lysate (LAL) assay (BioWhittaker, Walkersville,
MD, USA). The endotoxin level for all IgA preparation
was <1 pg/mg protein. Asialo-orosomucoid (ASOR) was
prepared by desialylation of human orosomucoid with
neuraminidase (0.03 U/mg protein) following incubation
for 8 hours at 37◦C in 0.1 mol/L sodium acetate buffer,
pH 5.0 [21]. Neutralizing antibodies to tumor necrosis
factor-a (TNF-a), interleukin-1b (IL-1b), transforming
growth factor-b (TGF-b), or platelet-derived growth fac-
tor (PDGF) were obtained from R&D Systems (Min-
neapolis, MN, USA). All other chemicals were obtained
from Sigma (St. Louis, MO, USA).
Patients and control subjects
Twenty-two Chinese patients (10 male and 12 female)
with clinical and renal immunopathologic diagnosis of
primary IgAN were studied. IgA nephropathy was diag-
nosed by the presence of predominant granular IgA de-
posits, mainly in the glomerular mesangium and occasion-
ally along the peripheral capillary basement membrane
by immunofluorescene examination, and the presence of
mesangial electron-dense deposits in ultrastructural ex-
amination. All the patients were symptomatic for more
than 12 months and no significant renal impairment was
documented. Systemic lupus erythematosus, Henoch-
Scho¨nlein purpura (HSP), and hepatic diseases were
excluded by detailed clinical history, examination and
negative laboratory findings for hypocomplementemia,
anti-DNA antibody, or hepatitis B virus surface antigen.
Twenty milliliters of blood was collected from each pa-
tient at clinical quiescence. The serum was isolated and
frozen at −20◦C until isolation of IgA by jacalin-agarose
affinity column.
Fifteen healthy subjects (7 male and 8 female), com-
parable in age and race, with no microscopic hematuria
or proteinuria, were recruited as normal control subjects.
Another 15 patients, 10 with minimal change nephropa-
thy (MCNS) and 5 with HSP, were also recruited as dis-
ease control patients. Serum was similarly collected from
these individuals for processing. Informed written con-
sent for blood sampling was obtained from every subject.
The study was carried out in accordance with the princi-
ples of the Declaration of Helsinki and was approved by
the university and hospital ethics committees.
Cell culture
Cell lines, including the colonic adenocarcinoma line
(HT29), the hepatocellular line (HepG2), and the mono-
cytic line (U937), were obtained from American Type
Culture Collection (ATCC; Rockville, MD, USA). These
cell lines, cultured under the condition recommended
by ATCC, were used as positive or negative control in
various experiments. Human peripheral blood mononu-
clear cells (PBMC) were isolated from healthy donors
by Ficoll gradient separation. Isolation and characteriza-
tion of human mesangial cells (HMC) were performed
as previously described [22]. Glomerular cells were
grown in RPMI 1640 medium supplemented with glu-
tamine (2 mmol/L), N-[2-hydroxyethyl]-piperazine-N’-
[2-ethanesulphonic acid] (HEPES) (10 mmol/L), peni-
cillin (50 U/mL), streptomycin (50 lg/mL) and 12% FBS.
The cells were incubated at 37◦C in 5% CO2 and 95%
air. Mesangial cells have a stellate appearance and grow
in clumps. They show a network of intracellular fibrils of
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Table 1. Primer sequences and size of PCR products
PCR product 5′ to 3′ sequences of PCR primers Size bp
FcaR 5′-TCG GGG TCT GGT GTT GAT GC-3′ 5′-GGA AAG TGT GGT GGG GAA GC-3′ 415
ASGPR H1 5′-AGC AAC TTC ACA GCG AGC AC-3′ 5′-TCC CGT CCA CCC ACT TCC AG-3′ 448
ASGPR H2 5′-GCA GGC TGA ATC CCA GGA GA-3′ 5′-CCA TTG AAG AGG CTG ACG AT-3′ 1072
pIgR 5′-GCA GTG GGG AAA ACT GTG AC-3′ 5′-GTC GCG GGG AAT CGT GGA CT-3′ 245
Fca/lR 5′-GAC AAC TAC CAA GGC TGA TAG G-3′ 5′-TCT GTC CCT CAG GGT CCT GGA T-3′ 702
TfR 5′-TTC TTT CTG TTT TTG CGA GGA C-3′ 5′-AAC GTC ACC AGA GAG GGC ATT T-3′ 601
TNF-a 5′-CAA TGG CGT GGA GCT GAG AGA-3′ 5′-CCA AAG TAG ACC TGC CCA GAC-3′ 345
ICAM-1 5′-GAG ACC CCG TTG CCT AAA-3′ 5′-CCG CAG GTC CAG TTC AGT-3′ 399
MIF 5′-CTC TCC GAG CTC ACC CAG CAG-3′ 5′-CGC GTT CAT GTC GTA ATA GTT-3′ 255
GAPDH 5′-ACC ACA GTC CAT GCC ATC AC-3′ 5′-TCC ACC ACC CTG TTG CTG TA-3′ 452
myosin and contract in the presence of 1 nmol/L of an-
giotensin II. Human PTEC were isolated as previously
described [23]. Tubular cells were grown in DMEM/F12
medium supplemented with glutamine (2 mmol/L), peni-
cillin (100 U/mL), streptomycin (100 lg/mL), hydrocor-
tisone (40 ng/mL), and 10% FBS at 37◦C in 5% CO2 and
95% air. These cells were characterized to be of proximal
tubular origin by immunofluorescence and enzyme his-
tochemistry [14]. In all experiments, cultured cells grown
to confluence were growth arrested with culture medium
containing 0.5% FBS for 48 hours before the commence-
ment of experiments.
Total RNA extraction and reverse transcription
(RT)-polymerase chain reaction (PCR)
Total cellular RNA was extracted using NucleoSpin
RNA II total RNA extraction kit (Macherey-Nagel,
Duren, Germany). The quality of the extracted RNA was
monitored by formaldehyde agarose gel electrophore-
sis. RNA was quantified by absorbance at 260 nm. Four
micrograms of total RNA was reverse transcribed to
cDNA with Moloney Murine Leukemia Virus reverse
transcriptase (Promega, Madison, WI, USA) in a 20 lL
reaction mixture containing 50 ng random hexamer,
0.5 mmol/L dNTPs, and 20 U of RNase inhibitor. The
cDNA was stored at −20◦C until further use. Gene ex-
pression of Fc alpha receptor 1 (FcaR or CD89), H1 and
H2 chains of asialoglycoprotein receptor (ASGPR H1
and ASGPR H2), polymeric-immunoglobulin receptor
(pIgR), Fc alpha/mu chain receptor (Fca/lR), transfer-
rin receptor (TfR or CD71), TNF-a, macrophage migra-
tion inhibitory factor (MIF), and intercellular adhesion
molecule-1 (ICAM-1) by PTEC were examined by PCR
using specific primers designed from known sequences
in the GenBank. The primer sequences are depicted in
Table 1. PCR products were analyzed by agarose gel elec-
trophoresis and stained with ethidium bromide. Images
of the gel were captured using the Gel Doc 1000 gel Doc-
umentation System from Bio-Rad (Hercules, CA, USA).
Gene expression of TNF-a, MIF, and ICAM-1 was then
analyzed by the IP Lab gel software from Signal Analyt-
ics (Vienna, VA, USA), and the results were expressed
as a ratio of the target amplicon to glyceraldehyde-
3-phosphate-dehydrogenase (GAPDH) amplicon. Full
precaution was taken for all necessary steps to ensure
the validity of the results as previously described [24].
Flow cytometry
Human mesangial cells or PTEC were grown to
log phase and harvested by using 0.05% trypsin/0.02%
EDTA for 5 minutes at room temperature. The cells were
adjusted to 5 × 106 per mL, and 200 lL of cell suspension
were used in binding assays. Staining was performed at
4◦C with staining buffer consisting of phosphate-buffered
saline (PBS) with 1% FBS and 0.1% sodium azide. The
cells were incubated with 100 lL of IgA (final concen-
tration 50 lg/mL) for 30 minutes. After incubation, the
cells were washed with staining buffer and then further
incubated with 100 lL of rabbit antihuman IgA anti-
body. Background control staining was achieved by re-
action with preimmune F(ab’)2 fragment of fluorescein
conjugated isotypic antibody. The stained cells were an-
alyzed using a Coulter EPICS XL analyzer (Miami, FL,
USA). A minimum of 5000 fixed cells for each sample was
analyzed. Fluorescence intensity was evaluated by com-
paring the mean fluorescence channels. The result was
expressed as mean fluorescence intensity (MFI).
Inhibition study
The fluorescein-conjugated pIgA (FITC-pIgA) or
mIgA (FITC-mIgA) was prepared from IgA prepara-
tion from each individual patient with IgAN using the
FluoReporter Protein Labeling Kits (Molecular Probe).
The effect of different potential blocking proteins on
IgA binding was examined by flow cytometry. Proxi-
mal tubular epithelial cells (1 × 106 cells in staining
buffer) were incubated with different blocking proteins,
including: 5 mg/mL unlabeled pIgA, 5 mg/mL unla-
beled mIgA, 5 mg/mL unlabeled IgG, 5 mg/mL unla-
beled IgM, 50 lg/mL Anti-sc, 5 mg/mL ASOR, 5 mg/mL
orosomucoid, 50 lg/mL My43, and 5 mg/mL transferrin,
for 30 minutes at 4◦C. After incubation, the cells were
washed once with staining buffer before incubation with
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0.5 mg/mL FITC-mIgA or FITC-pIgA. Following incu-
bation, the stained cells were washed and analyzed by
flow cytometry as described above.
Preparation of spent (conditioned) medium
Growth-arrested HMC were cultured in 6-well culture
plates (1 × 106 cells per well) with culture medium con-
taining 0.5% FBS and IgA (final concentration 50 lg/mL)
isolated from patients with IgAN, healthy control sub-
jects, and disease control patients for 48 hours. The
spent medium (IgA-HMC medium) after culture was
collected and kept frozen at −70◦C until used. Spent
medium from HMC cultured without the addition of IgA
preparation (control medium) was used as control. For
examining the effect of IgA-HMC medium on PTEC, dif-
ferent preparations of IgA-HMC medium were diluted
10-fold with DMEM/F12 containing 0.5% FBS for cul-
turing PTEC. Growth-arrested PTEC were seeded onto
6-well culture plates (1 × 106 cells per well) and were
cultured with diluted IgA-HMC medium for either 24
(for RT-PCR) or 48 hours (for ELISA). After culture,
the cells were collected for total RNA isolation, and the
supernatant was stored at −70◦C before assay of various
cytokines and chemokines. In order to study whether cy-
tokine and chemokine synthesis by PTEC was induced
via TNF-a in the IgA-HMC spent medium, similar ex-
periments were performed in cells incubated with anti-
bodies against TNF-a (0.1 lg/mL), IL-1b (0.1 lg/mL),
TGF-b (10 lg/mL), or PDGF (100 lg/mL) 1 hour before
stimulating with different spent medium. The concentra-
tion of neutralizing antibodies used was determined by
a preliminary experiment that demonstrated that TNF-a
(up to 1 ng/mL) induced up-regulation of MIF synthe-
sis in PTEC was abolished by incubating cells with neu-
tralizing anti-TNF-a at 0.1 lg/mL. The concentrations of
various neutralizing antibodies used were determined by
preliminary dose-determining experiments. MIF synthe-
sis up-regulated by TNF-a (up to 1 ng/mL), cell prolifer-
ation induced by PDGF (up to 10 ng/mL), IL-6 synthesis
induced by IL-1b (up to 10 ng/mL), or fibronectin syn-
thesis induced by TGF-b (up to 10 ng/mL) in PTEC was
abolished by incubating cells with neutralizing anti-TNF-
a at 0.1 lg/mL, anti-PDGF at 100 lg/mL, anti-IL-1b at
0.1 lg/mL, or anti-TGF-b at 10 lg/mL, respectively.
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay
Proliferation of cultured PTEC was determined using a
MTT assay kit (R&D Systems). Briefly, growth-arrested
PTEC were seeded onto 96-well plates (1 × 105 cells
per well) before stimulated with IgA preparation or IgA-
HMC medium for 48 hours. MTT reagent was then added
and incubated at 37◦C until purple precipitate was clearly
visible under an inverted microscope. Detergent reagent
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Fig. 1. Flow cytometry assay of IgA binding to PTEC and HMC. (A)
Binding of IgA from IgAN patients (N = 22) to PTEC and HMC is
increased when compared with healthy control subjects (N = 15). (B)
Representative histogram showing a lower binding of IgA to PTEC
than to HMC when same amount of IgA (50 lg/mL) and the equal
number of cells (1 × 106 cells) are used for the experiments.
was finally added and incubated in dark at 37◦C until the
purple precipitate was solubilized. The absorbance was
measured using 550 nm as the primary wavelength and
650 nm as the reference wavelength.
ELISA of TNF-a, MIF, sICAM-1, IL-1b, TGF-b, and
PDGF
Human TNF-a and soluble intercellular adhesion
molecule-1 (sICAM-1) were measured by commercially
available ELISA systems (Bender MedSystems, Vienna,
Austria). Human IL-1b , TGF-b , and PDGF-B were
assayed using sandwich ELISA (R&D Systems). Im-
munoreactive MIF was quantitated by a sandwich ELISA
as described previously [25].
Statistical analysis
All data were expressed as mean ± standard devia-
tion (SD) unless otherwise specified. Statistical differ-
ence was analyzed with multivariate analysis of variance
(ANOVA) for repeated measures. All P values quoted
are two-tailed, and the significance is defined as P < 0.05.
RESULTS
Binding of IgA to PTEC and HMC
Figure 1A shows the binding of total IgA to PTEC
or HMC determined by flow cytometry. The binding of
606 Chan et al: Renal tubular cell activation in IgAN
FcαR
ASGPR H1
ASGPR H2
plgR
TfR
Fcα/µR
10
0 
bp
 m
ar
ke
r
HT
29
He
pG
2
HM
C
PT
EC
 (li
ne
 1)
PT
EC
 (li
ne
 2)
PT
EC
 (li
ne
 3)
PB
M
C
U9
37
Ne
g 
ctl
10
0 
bp
 m
ar
ke
r
HT
29
He
pG
2
HM
C
PT
EC
 (li
ne
 1)
PT
EC
 (li
ne
 2)
PT
EC
 (li
ne
 3)
PB
M
C
U9
37
Ne
g 
ctl Fig. 2. mRNA expression of IgA receptorsby reverse transcription-polymerase chain re-
action (RT-PCR). PTEC do not express
mRNA of known IgA receptors, including
FcaR, pIgR, and Fca/lR, except TfR. As for
ASGPR, only the H1 chain of the ASGPR is
expressed in PTEC.
Table 2. Semiquantitative analysis of the expression of IgA receptors (from zero to 3+)
FcaR ASGPR H1 ASGPR H2 pIgR TfR Fca/lR GAPDH
HT29 – + – ++ +++ – +++
HepG2 – ++++ +++ + +++ – +++
HMC – – – – +++ + +++
PTEC-1 – + – – +++ – +++
PTEC-2 – + – – +++ – +++
PTEC-3 – + – – +++ – +++
PBMC ++ ++ – Weakly + +++ + +++
U937 +++ Weakly + – – +++ – +++
Negative control – – – – – – –
IgA from IgAN patients to either cell type was higher
than the binding of IgA from healthy control subjects
(PTEC: 1.02 ± 0.26 vs. 0.82 ± 0.52; P < 0.005, and HMC:
9.07 ± 2.30 vs. 6.52 ± 1.55; P < 0.001). However, using
identical concentration of IgA and same number of cells
in the binding assay, the binding of IgA to PTEC was
only 8.6% and 8.9% of the binding of IgA to HMC for
IgAN patients and healthy control subjects, respectively
(Fig. 1B).
Expression of surface IgA receptors in PTEC
Figure 2 depicts the mRNA expression of the FcaR,
H1 and H2 chains of ASGPR, pIgR, Fca/lR, and the
transferrin receptors (TfR) in PTEC. Human mesangial
cells and other cell lines were used as positive control for
gene expression of different receptors. The findings are
summarized in Table 2. PTEC did not express mRNA
for any known IgA receptors except the transferrin re-
ceptor. The expression pattern was identical when three
individual PTEC lines from different donors were used.
Although the H1 chain mRNA was expressed in PTEC,
there was no expression of ASGPR H2 chain, which was
required for assembling a functional ASGPR.
Inhibition study of IgA binding to PTEC by competitor
proteins
Figure 3 shows the inhibition studies in IgA binding
to PTEC. The binding of FITC-mIgA or FITC-pIgA to
PTEC was not blocked by preincubation with proteins
that competitively blocked individual known IgA recep-
tors, including IgM, anti-sc, ASOR, orosomucoid, anti-
FcaR1 (clone My43), and transferrin. The binding of
FITC-mIgA was reduced by 75% and 87% when the
cells were preincubated with unlabeled mIgA and pIgA,
respectively (P < 0.0001 for both). The binding of FITC-
pIgA to PTEC was only reduced by 42% following prein-
cubation with unlabeled mIgA (P < 0.005). In contrast,
the binding of FITC-pIgA to PTEC was markedly re-
duced (∼90%) following preincubation with unlabeled
pIgA (P < 0.0001).
Cell proliferation of PTEC cultured with IgA
Despite the detection of binding of mIgA or pIgA to
cultured PTEC, enhanced cell proliferation (measured
by MTT assay) was not observed when incubated with
IgA isolated from patients with IgAN or healthy control
subjects (data not shown). The lack of cell proliferation
was supported by the findings that the synthesis of TNF-
a, MIF, or sICAM-1 in PTEC did not differ between
culture experiments with IgA preparations from IgAN
patients, healthy control subjects, or disease control pa-
tients (Fig. 4). The findings in gene expression of these
mediators paralleled those of protein synthesis (data not
shown).
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Fig. 3. Inhibition binding assay. Inhibition of competitor proteins on
the binding of (A) FITC-mIgA or (B) FITC-pIgA to PTEC. The binding
of FITC-mIgA or FITC-pIgA (solid bars) to PTEC is not blocked by
preincubating PTEC with different competitor proteins (dotted bars).
Open bar represents the background MFI using isotype antibody as con-
trol. Preincubation of PTEC with mIgA and pIgA results in reduction
of FITC-mIgA binding by 75% and 86.5%, respectively. Preincubation
of PTEC with mIgA and pIgA results in reduction of FITC-pIgA bind-
ing by 42% and 90%, respectively. The results represent the mean ±
standard deviation from 5 individual experiments.
Cell proliferation study in PTEC cultured with IgA-HMC
medium
We then explored whether IgA-HMC medium from
patients with IgAN exhibited any stimulatory effect on
cultured PTEC. Cell proliferation was higher in PTEC
incubated with IgA-HMC medium from patients with
IgAN than that from healthy control subjects (P < 0.001)
(Fig. 5). However, IgA-HMC from other disease control
patients (MCNS and HSP) did not exert any enhance-
ment on the proliferation of PTEC.
Gene expression and protein synthesis of TNF-a, MIF,
and ICAM-1 by PTEC cultured with IgA-HMC medium
Both gene expression and protein synthesis of TNF-a,
MIF, and ICAM-1 were up-regulated when PTEC were
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Fig. 4. Protein synthesis of TNF-a, MIF, and sICAM-1 in PTEC in-
cubated with IgA. There is no difference in protein synthesis of (A)
TNF-a, (B) MIF, and (C) sICAM1 when PTEC are incubated with to-
tal IgA prepared from patients with IgA nephropathy (IgAN), minimal
change nephropathy (MCNS), or Henoch-Scho¨nlein purpura (HSP) as
compared with IgA from healthy control subjects (Ctl) or incubation
with culture medium alone (Medium Ctl).
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Fig. 5. Cell proliferation assay of PTEC incubated with IgA-HMC
spent medium. Increased proliferation of PTEC is observed when cul-
tured with IgA-HMC spent medium prepared from IgAN patients when
compared with healthy control subjects (Ctl). PTEC incubated with
IgA-HMC spent medium from patients with minimal change nephropa-
thy (MCNS) or with Henoch-Scho¨nlein purpura (HSP) demonstrate no
increased proliferation when compared to IgA isolated from healthy
control subjects. #P < 0.001 vs. IgAN.
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Fig. 6. Expression of TNF-a, MIF, and ICAM-1 in PTEC incubated with IgA-HMC spent medium. The gene expression of (A) TNF-a, (B) MIF,
and (C) ICAM-1 is up-regulated in PTEC incubated with IgA-HMC spent medium prepared from IgAN patients when compared to that from
healthy control subjects (Ctl). Gene expression of TNF-a or MIF is not increased in PTEC incubated with IgA-HMC spent medium prepared from
patients with minimal change nephropathy (MCNS) or with Henoch-Scho¨nlein purpura (HSP) when compared with that of healthy control subjects.
The protein synthesis of (D) TNF-a, (E) MIF, and (F) sICAM-1 is up-regulated in PTEC incubated with IgA-HMC spent medium prepared from
IgAN patients when compared to that from healthy control subjects (Ctl). Protein synthesis of TNF-a, MIF, or sICAM-1 is not increased in PTEC
incubated with IgA-HMC spent medium prepared from patients with minimal change nephropathy (MCNS) or with Henoch-Scho¨nlein purpura
(HSP) when compared with that of healthy control subjects. #P < 0.01 vs. IgAN and ∗P < 0.01 vs. Ctl.
incubated with IgA-HMC medium from IgAN patients
when compared with IgA-HMC from healthy control
subjects (P < 0.001) or from disease control patients (P <
0.01) (Fig. 6). There was no increase in gene expression or
protein synthesis of TNF-a and MIF in PTEC incubated
with IgA-HMC medium from patients with MCNS or
HSP when compared with that of healthy control subjects.
However, the gene expression of ICAM-1 was slightly in-
creased in PTEC incubated with IgA-HMC medium from
patients with MCNS when compared with that of healthy
control subjects (P < 0.01).
The concentration of TNF-a, IL-1b, TGF-b, and PDGF
in the IgA-HMC medium
The concentration of TNF-a in the IgA-HMC medium
was determined to rule out the possibility that the level
of TNF-a synthesis by PTEC after cultured with IgA-
HMC medium was directly derived from the IgA-HMC
medium. The synthesis of TNF-a was up-regulated in
HMC incubated with IgA from patients with IgAN
(Fig. 7). Following a 10-fold dilution, the calculated TNF-
a concentration of the diluted spent medium used in cul-
ture experiments was 43.27 pg/mL. This concentration
was less than one quarter of the supernatant concentra-
tion of PTEC cultured with the diluted spent medium
from HMC incubated with IgA from IgAN patients.
The synthesis of TGF-b was up-regulated in HMC incu-
bated with IgA from patients with IgAN when compared
with healthy control subjects (397.16 ± 49.60 pg/mL vs.
308.89 ± 39.02 pg/mL; P = 0.0003). There was no induc-
tion of PDGF synthesis in HMC incubated with IgA from
patients with IgAN or control subjects as compared with
basal PDGF level (data not shown). No IL-1b was de-
tected in the medium of HMC incubated with IgA from
patients or control subjects.
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Fig. 7. Synthesis of TNF-a in HMC incubated with IgA. TNF-a is up-
regulated when HMC are incubated with IgA prepared from IgAN
patients as compared to healthy control subjects (Ctl). TNF-a synthesis
is not increased in HMC incubated with IgA prepared from patients
with minimal change nephropathy (MCNS) or with Henoch-Scho¨nlein
purpura (HSP) when compared with that of the Ctl. #P < 0.001.
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Fig. 8. Synthesis of MIF and sICAM-1 by PTEC incubated with IgA-
HMC spent medium in the presence of a neutralizing anti-TNF-a an-
tibody. A neutralizing anti-TNF-a at a concentration of 0.1 lg/mL
(shaded bar) down-regulates (A) MIF and (B) sICAM-1 synthesis in
PTEC incubated with IgA-HMC spent medium from patients with
IgAN as compared with IgA-HMC spent medium from control subjects.
Effect of neutralizing antibodies in the protein synthesis
of MIF and sICAM-1 by PTEC cultured with IgA-HMC
medium
We then investigated the potential effect of a neu-
tralizing anti-TNF-a antibody in modulating the protein
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Fig. 9. Synthesis of MIF and sICAM-1 by PTEC incubated with IgA-
HMC spent medium in the presence of neutralizing antibodies to TNF-
a, IL-1b, TGF-b, or PDGF. Only the neutralizing anti-TNF-a (shaded
bar) down-regulates (A) MIF and (B) sICAM-1 synthesis in PTEC
incubated with IgA-HMC spent medium (black bar) from patients with
IgAN as compared with IgA-HMC spent medium from control subjects
(white bar). Synthesis of MIF or sICAM-1 is not reduced by neutralizing
antibodies to IL-1b , TGF-b , or PDGF.
synthesis of MIF and sICAM-1 in PTEC incubated with
IgA-HMC medium from patients with IgAN. Anti-TNF-
a antibody at a concentration of 0.1 lg/mL completely
abolished MIF protein synthesis (when compared with
IgA-HMC medium from control) (Fig. 8A) and down-
regulated sICAM-1 synthesis by 39% (Fig. 8B). Of note,
the down-regulatory effect on MIF (Fig. 9A) or sICAM-1
synthesis (Fig. 9B) was only demonstrated in neutralizing
anti-TNF-a antibody, but not with neutralizing antibod-
ies to IL-1b , TGF-b , or PDGF.
DISCUSSION
In IgAN, mesangial IgA deposition is an early event
that may subsequently lead to glomerular and tubular
damages in a slowly but progressive clinical course. The
binding of IgA to HMC is increased in IgAN [1, 26]. The
interaction of IgA with glomerular mesangial cells in-
duces cell proliferation [27] and the release of cytokines
and chemokines [26, 28]. Tubulointerstitial damage lead-
ing to end-stage renal failure is a common sequel in most
chronic kidney disease, including IgAN [9]. Increase in
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urinary IgA concentration has been reported in IgAN,
and the level of urinary IgA correlates with the serum
creatinine as well as the urinary protein excretion [28]. In
addition, the duration and extent of proteinuria are useful
predictors for glomerular and interstitial damage in IgAN
[29]. It is possible that the tubular lumen is constantly ex-
posed to the high molecular weight IgA from patients
with IgAN, especially when glomerular size barrier is im-
paired in IgAN [30]. Because significant proteinuria or
nephrotic syndrome is not a common finding in IgAN, it
is, therefore, important to know whether IgA can bind to
PTEC and elicit any functional activation as observed in
HMC.
We found increased binding of IgA from patients with
IgAN to cultured PTEC as compared to binding of IgA
from healthy control subjects. However, the quantity of
IgA bound to PTEC was less than one tenth that of HMC
in IgAN, thus raising the question whether the binding
observed in the cell culture experiments was not specific.
We then examined the expression of known IgA recep-
tors to determine the binding was mediated through these
receptors. We demonstrated that PTEC did not express
any known IgA receptors except for the TfR and the H1
chain of the ASGPR, which failed to assemble a func-
tional ASGPR due to the lack of the H2 chain. To further
exclude whether the binding of IgA to PTEC was through
the TfR or the other known IgA receptors, we conducted
competitive binding studies using different ligands for
known IgA receptors. Different competitor proteins for
IgA receptors did not inhibit the binding of FITC-labeled
pIgA or mIgA to PTEC. Most interestingly, we failed to
show blocking of the IgA binding to PTEC by transferrin.
Our observation is in accordance with the recent report
showing that glomerular IgA deposition was only asso-
ciated with the expression of glomerular TfR, but not
with the tubular TfR [31]. Furthermore, despite positive
immunostaining of TfR that was evident in glomerular
mesangium and renal tubules, enhanced expression of
TfR was only observed in the mesangium in patients with
IgAN. The lack of cell proliferation and absence of func-
tional activities measured by synthesis of TNF-a, MIF,
or sICAM-1 in PTEC incubated with IgA preparations
from IgAN adds further support to the notion that the
low level of IgA binding to cultured PTEC represents a
nonspecific binding in cell culture experiments. This con-
clusion is in accordance with the histologic finding that
IgA deposits are rarely detected in the tubulointersti-
tium in IgAN [16]. Aberrant glycosylation of O-glycans
and the electrostatic interaction due to the anionic nature
of the IgA molecule may be operative in the binding of
IgA to HMC in IgAN [22, 32]. Increased binding of IgA to
various components of ECM had been demonstrated in
IgAN [33]. Whether similar mechanisms are operated for
the nonspecific binding of IgA to cultured PTEC remain
to be explored.
Based on our findings, we propose that tubular ac-
tivation and interstitial injury in IgAN are not due to
the direct exposure of PTEC to IgA within the tubu-
lar lumen. Other than the tubulotoxic role of protein-
uria, we hypothesize that mediators or soluble factors
released from HMC following IgA deposition lead to
PTEC activation. The concept that a glomerulotubular
cross-talk in IgAN is novel, but communication between
compartments of the nephron has been reported by oth-
ers and us. A tubuloglomerular cross-talk exists during
heavy proteinuria, leading to glomerulosclerosis [14]. Re-
cently, mesangial cells have been found to communicate
with podocytes through interferon-inducible protein-10
[34]. To confirm our hypothesis, we conducted PTEC cul-
ture experiments using spent medium from HMC prein-
cubated with different IgA preparations. This medium
transfer setting allowed no direct cell-cell communication
but simulated the in vivo glomerulotubular communica-
tion via humoral factors. Spent medium from HMC incu-
bated with IgA from patients with IgAN, but not with IgA
from MCNS, HSP, or healthy subjects, increased PTEC
proliferation. Simultaneously, there was up-regulation in
the gene expression and protein synthesis of TNF-a, MIF,
and ICAM-1 in PTEC cultured with IgA-HMC spent
medium from patients with IgAN. The increased synthe-
sis of TNF-a after culturing with IgA-HMC medium was
not due to the ‘left over’ from the HMC spent medium
because there was enhanced gene expression of TNF-a
in the PTEC. Moreover, the concentration of TNF-a in
the supernatant of cultured PTEC was at least 4-fold
higher than that in the IgA-HMC medium. These ob-
servations are in line with recent studies reporting an
up-regulation of MIF and ICAM-1 expression in the
tubular cells from patients with IgAN [35, 36]. Urinary
excretion of MIF is increased in patients with IgAN,
and the level correlates with the disease activity [37].
Mesangial cells can be activated to produce cytokines and
chemokines, including IL-1, IL-6, TNF-a, MCP-1, TGF-
b , and PDGF [38, 39]. We speculate that these humoral
factors/mediators from mesangial cells may reach the
tubulointerstitium either by glomerular filtration or by
transportation via the postglomerular capillaries. Upon
reaching the tubular compartment, these mediators could
stimulate PTEC to produce other proinflammatory cy-
tokines and chemokines that eventually lead to tubular
damage, interstitial mononuclear cell infiltration, and fi-
brosis. One of the possible mediators is TNF-a produced
by HMC following stimulation by pIgA from IgAN pa-
tients [25]. Our finding of increased synthesis of TNF-a
by PTEC exposed to IgA-HMC spent medium suggests
an autocrine effect of the cytokine. Moreover, the result
from culture experiments using neutralizing anti-TNF-a
antibody suggests that TNF-a is a potent mediator, at
least for MIF synthesis, in PTEC exposed to IgA-HMC
spent medium. The continuous and local synthesis of
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these inflammatory cytokines and chemokines plays an
important role in the pathogenesis of chronic tubuloin-
terstitial injury in IgAN [40]. Since sICAM-1 synthesis
by PTEC exposed to IgA-HMC spent medium was only
partially blocked by neutralizing anti-TNF-a antibody,
we further examined the synthesis MIF and sICAM-1
by PTEC activated with IgA-HMC spent medium in the
presence of other neutralizing antibodies to potential me-
diators, including IL-1b , TGF-b , or PDGF. As predicted,
neutralizing antibodies to IL-1b or PDGF did not re-
duce the synthesis of MIF or sICAM-1 by PTEC cultured
with IgA-HMC spent medium because we had detected
no induction of PDGF or IL-1b synthesis in HMC incu-
bated with IgA from patients with IgAN. Anti-TGF-b did
not reduce the synthesis of MIF or sICAM-1 by PTEC
cultured with IgA-HMC spent medium. This could be
because the concentration of TGF-b in the IgA-HMC
medium (∼40 pg/mL) is not high enough to elicit these
inflammatory responses as observed by other investiga-
tors [41]. Taken together, our finding suggests that other
mediators released from HMC activated by pIgA may
also take part in inducing the tubulointerstitial injury, and
further investigation is warranted.
Our experiments showed that spent medium from
HMC incubated with IgA from patients with IgAN, but
not with IgA from control subjects, increased prolifera-
tion and synthesis of TNF-a, MIF, or ICAM-1 in PTEC.
Of note is the different finding between IgAN and HSP,
despite the latter having similar renal histopathology.
This could be due to the difference in the size of circu-
lating IgA immune complexes, the subclass of IgA (k−
versus j−light chain) deposited in the mesangium, and
the regulation of B cells by T lymphocytes between the
two glomerulonephritides (review in [42]). The difference
in the functional effect on mesangial cells (such as syn-
thesis of MIF and angiotensin II) between polymeric IgA
isolated from patients with IgAN and patients with HSP
has previously been documented [25, 43].
CONCLUSION
The absence of IgA binding through known IgA re-
ceptors, and the lack of PTEC activation, supports the
notion that IgA is rarely deposited in the tubulointer-
stitium in IgAN. However, we have shown that media-
tors released from HMC after mesangial IgA deposition
can activate PTEC and lead to subsequent inflammatory
changes in PTEC. Our finding implicates that humoral
factors released from glomerular mesangium maintain a
glomerulotubular cross-talk in the development of tubu-
lointerstitial damage in IgAN.
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